An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas
Categories (click each to see list of all clinical trials associated with that category): Brain/Neuro
Current Status: Open to accrual
Phase: N/A
Principal Investigator: Shonka, Nicole
Contact Information:
Sarah Kirke, RN
402-559-8065
sarah.kirke@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/NCT03259633?cond=NCT03259633&draw=2&rank=1#eligibility
Summary
To provide compassionate access to selumetinib to patients for the treatment of NF1 with inoperable, progressive/symptomatic PN.